Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation

被引:21
作者
Pastori, Daniele [1 ,2 ]
Farcomeni, Alessio [3 ]
Saliola, Mirella [1 ]
Del Sole, Francesco [1 ]
Pignatelli, Pasquale [1 ]
Violi, Francesco [1 ]
Lip, Gregory Y. H. [2 ,4 ]
机构
[1] Sapienza Univ Rome, Dept Internal Med & Med Specialties, Clin Med 1, Atherothrombosis Ctr, Rome, Italy
[2] Univ Birmingham, Inst Cardiovasc Sci, Birmingham, W Midlands, England
[3] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Rome, Italy
[4] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark
关键词
Atrial fibrillation; Anticoagulation; Vitamin K antagonists; Time in therapeutic range; Cardiovascular events; PROTON PUMP INHIBITORS; ANTICOAGULATION CONTROL; ORAL ANTICOAGULATION; WARFARIN; QUALITY; RISK; EFFICACY; ASPIRIN; STROKE; SAFETY;
D O I
10.1016/j.ejim.2018.04.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Optimal time in therapeutic range (TTR) of vitamin K antagonists (VKAs) is crucial for cardiovascular events (CVEs) prevention in non-valvular atrial fibrillation (NVAF). The relationship between temporal changes of TTR and the incidence of CVEs has been poorly investigated. We investigated 1) temporal trends of TTR in a long-term follow-up of NVAF patients; 2) the incidence of CVEs according to changes of TTR. Methods: Prospective observational study including 1341 NVAF outpatients (mean age 73.5 years, 42.5% male) starting VKAs. Patients were divided into 4 groups: Group 0: Optimal TTR, consistently >= 70% (n = 241); Group 1: Temporally worsening TTR, from above to below 70% (n = 263); Group 2: Temporally improving TTR, from below to above 70% (n = 270); Group 3: Suboptimal TTR, consistently < 70% (n = 567). Results: In a mean follow-up of 37.7 months (4214.2 patient-years), 108 CVEs occurred (2.6%/year). Survival analysis showed a graded increased risk of CVEs in relation to temporal changes in TTR, with the worst outcomes in Groups 1 and 3 (log-rank test p = 0.013). Multivariable Cox proportional hazards regression analysis showed that Group 1 vs. 0 (HR: 2.096; 95%CI 1.061-4.139, p = 0.033), Group 3 vs. 0 (HR: 2.292; 95%CI 1.205-4.361, p = 0.011), CHA(2)DS(2)VASc score (HR:1.316; 95%CI 1.153-1.501, p < 0.001) and PPIs (HR:0.453; 95%CI 0.285-0.721, p = 0.001) were independently associated with CVEs. Conclusion: A decrease of TTR < 70% over time is observed in almost 20% of NVAF patients. Patients with worsening TTR temporally (ie. from initially above 70% to below 70%) have similar risk of CVEs of patients with consistently suboptimal anticoagulation.
引用
收藏
页码:34 / 39
页数:6
相关论文
共 32 条
[21]   Incidence of Myocardial Infarction and Vascular Death in Elderly Patients With Atrial Fibrillation Taking Anticoagulants Relation to Atherosclerotic Risk Factors [J].
Pastori, Daniele ;
Pignatelli, Pasquale ;
Angelico, Francesco ;
Farcomeni, Alessio ;
Del Ben, Maria ;
Vicario, Tommasa ;
Bucci, Tommaso ;
Raparelli, Valeria ;
Cangemi, Roberto ;
Tanzilli, Gaetano ;
Lip, Gregory Y. H. ;
Violi, Francesco .
CHEST, 2015, 147 (06) :1644-1650
[22]   The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease [J].
Pastori, Daniele ;
Polimeni, Licia ;
Baratta, Francesco ;
Pani, Arianna ;
Del Ben, Maria ;
Angelico, Francesco .
DIGESTIVE AND LIVER DISEASE, 2015, 47 (01) :4-11
[23]   Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials [J].
Proietti, Marco ;
Lane, Deirdre A. ;
Lip, Gregory Y. H. .
EBIOMEDICINE, 2016, 8 :309-316
[24]   Adherence to oral anticoagulant therapy in patients with atrial fibrillation Focus on non-vitamin K antagonist oral anticoagulants [J].
Raparelli, Valeria ;
Proietti, Marco ;
Cangemi, Roberto ;
Lip, Gregory Y. H. ;
Lane, Deirdre A. ;
Basili, Stefania .
THROMBOSIS AND HAEMOSTASIS, 2017, 117 (02) :209-218
[25]   Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients [J].
Rivera-Caravaca, Jose Miguel ;
Roldan, Vanessa ;
Asuncion Esteve-Pastor, Maria ;
Valdes, Mariano ;
Vicente, Vicente ;
Lip, Gregory Y. H. ;
Marin, Francisco .
THROMBOSIS AND HAEMOSTASIS, 2017, 117 (07) :1448-1454
[26]   Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA) [J].
Rose, A. J. ;
Hylek, E. M. ;
Ozonoff, A. ;
Ash, A. S. ;
Reisman, J. I. ;
Berlowitz, D. R. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (10) :2182-2191
[27]  
ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236
[28]   Safety and efficacy of well managed warfarin A report from the Swedish quality register Auricula [J].
Sjogren, Vilhelm ;
Grzymala-Lubanski, Bartosz ;
Renlund, Henrik ;
Friberg, Leif ;
Lip, Gregory Y. H. ;
Svensson, Peter J. ;
Sjalander, Anders .
THROMBOSIS AND HAEMOSTASIS, 2015, 113 (06) :1370-1377
[29]   Atrial Fibrillation and Acid Reflux Disease [J].
Velagapudi, Poonam ;
Turagam, Mohit K. ;
Leal, Miguel A. ;
Kocheril, Abraham G. .
CLINICAL CARDIOLOGY, 2012, 35 (03) :180-186
[30]   Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms [J].
Violi, Francesco ;
Soliman, Elsayed Z. ;
Pignatelli, Pasquale ;
Pastori, Daniele .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (05)